Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRT2379
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SRT2379 is a selective small-molecule activator of the NAD+-dependent deacetylase, sirtuin 1 (SIRT1). It was developed as a novel anti-inflammatory agent with potential applications in metabolic and inflammatory diseases. Preclinical studies demonstrated that SRT2379 could inhibit systemic inflammation induced by lipopolysaccharide (LPS) in animal models. The drug was primarily investigated for its effects on endotoxin-induced inflammation and for the treatment of type 2 diabetes and sepsis. Clinical development reached phase 1 trials, but there are no approved indications or ongoing advanced clinical programs[2][3][5][6].
- Other names
- SRT 2379SRT2379SRT-2379
02
Targets
SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on SRT2379.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRT2379.